Precision Oncology

Introduction: Biology Does Not Happen One Modality at a Time If genomics gives us the blueprint, transcriptomics shows what is being transcribed, proteomics shows what machinery is actually present, and metabolomics shows the biochemical consequences, then a single-omics analysis is always partial by construction. That is not a flaw in any one assay; it is a fact about biology. Cells regulate themselves through layered, noisy, nonlinear interactions. A DNA mutation may have no phenotypic consequence if the transcript is silenced. A dramatic RNA change may not matter if protein abundance is buffered. A protein-level perturbation may only become visible when a pathway rewires metabolism. ...

The Ultimate Test: Does It Help Patients? After eighteen posts exploring the technical landscape of agentic omics—from foundation models for DNA and proteins to multi-agent systems for drug discovery—we arrive at the question that matters most: does any of this actually improve patient outcomes? The answer is more nuanced than the hype suggests. As of early 2026, the FDA has approved over 1,000 AI/ML-enabled medical devices, but only a small fraction operate on genomic or pathology data with demonstrated clinical utility (IntuitionLabs, 2025; Nature Digital Medicine, 2025). The gap between a model that achieves 95% accuracy on a benchmark and a tool that measurably extends survival remains wide—and crossing it requires navigating regulatory pathways, clinical validation studies, and the messy reality of healthcare IT infrastructure. ...

Introduction: The Precision Oncology Imperative Cancer is not one disease but hundreds—each with distinct molecular drivers, treatment responses, and clinical trajectories. The promise of precision oncology is simple in concept but staggering in execution: match the right treatment to the right patient at the right time, guided by the molecular profile of their tumor. In practice, this requires orchestrating a complex workflow: tumor sequencing to identify mutations, interpretation of those variants against clinical databases, integration of genomic data with transcriptomic and proteomic profiles, therapy matching against drug databases, clinical trial matching, and longitudinal monitoring for resistance and recurrence. Each step generates data, requires expert interpretation, and carries uncertainty. ...